Otros idiomas Gossamer Bio, Inc.

Acciones

GOSS

US38341P1021

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 06/12/2024			Varia. Cinco días.	Varia. 1 de enero.
0,7532 ^USD	+5,30 %		+7,89 %	-17,46 %

07/11	Gossamer Bio, Inc. informa de los resultados del tercer trimestre y de los nueve meses finalizados el 30 de septiembre de 2024	CI
04/09	Bolt Biotherapeutics, Inc. anuncia cambios en su Consejo de Administración	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Gossamer Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(4)	12/11
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	11/11
Gossamer Bio: Q3 Earnings Snapshot	07/11
Earnings Flash (GOSS) GOSSAMER BIO Reports Q3 Revenue $9.5M	07/11
Earnings Flash (GOSS) GOSSAMER BIO Reports Q3 Loss $-0.14	07/11
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update	07/11
Gossamer Bio : Announces Third Quarter 2024 Financial Results and Provides Business Update Form 8 K	07/11
Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	07/11
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	07/10
Bolt Biotherapeutics, Inc. Announces Changes to Its Board of Directors	04/09
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024	26/08
Gossamer Bio: Q2 Earnings Snapshot	12/08
Earnings Flash (GOSS) GOSSAMER BIO Reports Q2 Revenue $95.8M	12/08
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update	12/08
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	12/08
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	07/06
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference	14/05
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	10/05
Gossamer Bio: Q1 Earnings Snapshot	07/05
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update	07/05
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Gossamer bio announces publication of torrey phase 2 results in the lancet respiratory medicine	06/05
Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	06/05
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment	06/05
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications	06/05

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Gossamer Bio, Inc.

Acciones

GOSS

US38341P1021

Biotecnología e investigación médica

Otros idiomas

Filtros